Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Anavex Lf SC (AVXL)

Anavex Lf SC (AVXL)
8.75 x 3 9.01 x 5
Pre-market by (Cboe BZX)
8.70 +0.18 (+2.11%) 02/18/25 [NASDAQ]
8.75 x 3 9.01 x 5
Pre-market 8.70 unch (unch) 16:00 ET
Quote Overview for Tue, Feb 18th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
8.52
Day High
9.20
Open 8.54
Previous Close 8.52 8.52
Volume 1,202,300 1,202,300
Avg Vol 1,080,215 1,080,215
Stochastic %K 31.31% 31.31%
Weighted Alpha +6.40 +6.40
5-Day Change -0.11 (-1.25%) -0.11 (-1.25%)
52-Week Range 3.25 - 14.44 3.25 - 14.44
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 740,057
  • Shares Outstanding, K 85,064
  • Annual Sales, $ 0 K
  • Annual Income, $ -43,000 K
  • EBIT $ -55 M
  • EBITDA $ -55 M
  • 60-Month Beta 0.69
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.48

Options Overview Details

View History
  • Implied Volatility 79.11% ( -22.13%)
  • Historical Volatility 85.35%
  • IV Percentile 31%
  • IV Rank 16.04%
  • IV High 388.12% on 04/04/24
  • IV Low 20.06% on 05/01/24
  • Put/Call Vol Ratio 0.14
  • Today's Volume 1,882
  • Volume Avg (30-Day) 1,395
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 55,606
  • Open Int (30-Day) 50,618

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.18
  • Number of Estimates 1
  • High Estimate -0.18
  • Low Estimate -0.18
  • Prior Year -0.13
  • Growth Rate Est. (year over year) -38.46%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.91 +9.99%
on 02/12/25
Period Open: 9.21
10.80 -19.44%
on 01/24/25
-0.51 (-5.54%)
since 01/17/25
3-Month
7.31 +19.02%
on 11/19/24
Period Open: 7.45
14.44 -39.75%
on 12/26/24
+1.25 (+16.78%)
since 11/18/24
52-Week
3.25 +167.69%
on 04/25/24
Period Open: 5.67
14.44 -39.75%
on 12/26/24
+3.03 (+53.44%)
since 02/16/24

Most Recent Stories

More News
Anavex Life Sciences: Fiscal Q1 Earnings Snapshot

Anavex Life Sciences: Fiscal Q1 Earnings Snapshot

AVXL : 8.70 (+2.11%)
Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

AVXL : 8.70 (+2.11%)
Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025

AVXL : 8.70 (+2.11%)
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

AVXL : 8.70 (+2.11%)
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease

AVXL : 8.70 (+2.11%)
Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Drug Buzz

The intense retail focus on Anavex reflects a broader market interest in neurodegenerative therapies, especially following disappointing trial results from Cassava Sciences’ simufilam.

AVXL : 8.70 (+2.11%)
RIGL : 20.74 (-3.85%)
NVAX : 8.25 (+0.73%)
New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients

AVXL : 8.70 (+2.11%)
Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

AVXL : 8.70 (+2.11%)
Short-Squeeze Target Anavex Life Sciences Gains Traction

Anavex Life Sciences stock market is set up for a short squeeze that could begin in early 2025 and increase the price by 400% or more.

AVXL : 8.70 (+2.11%)
Anavex Sciences Soars On Earnings Relief, EU Filing Acceptance For Alzheimer’s Drug: Retail’s Overjoyed

The broader market’s interest in Alzheimer’s therapies remains intense, particularly after Cassava Sciences reported disappointing results for its candidate simufilam last month.

AVXL : 8.70 (+2.11%)
SAVA : 2.57 (+6.20%)

Business Summary

ANAVEX LIFE SCIENCES CORP. is an emerging biopharmaceutical company engaged in the discovery and development of novel drug targets for the treatment of cancer and neurological diseases. The company's proprietary SIGMACEPTOR Discovery Platform involves the rational drug design of compounds that fulfill...

See More

Key Turning Points

3rd Resistance Point 9.78
2nd Resistance Point 9.49
1st Resistance Point 9.09
Last Price 8.70
1st Support Level 8.41
2nd Support Level 8.13
3rd Support Level 7.73

See More

52-Week High 14.44
Fibonacci 61.8% 10.17
Fibonacci 50% 8.85
Last Price 8.70
Fibonacci 38.2% 7.52
52-Week Low 3.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Increase Profitable Opportunities with Barchart's Technical Opinion